de Mooij-van Malsen Annetrude J G, Olivier Berend, Kas Martien J H
Rudolf Magnus Institute of Neuroscience, Department of Neuroscience and Pharmacology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Eur J Pharmacol. 2008 May 13;585(2-3):436-40. doi: 10.1016/j.ejphar.2008.01.057. Epub 2008 Mar 18.
The pharmacological treatment of mood and anxiety disorders has for long relied on the serendipitous findings of monoaminergic and benzodiazepine drugs more than 50 years ago. These treatments, however, are therapeutically insufficient and even though more recently developed drugs are particularly improving side effects, the efficacy or response rate of the drugs has fundamentally not improved. Therefore it is necessary to develop new methods to identify novel mechanisms not based on merely the symptomatology, but on biologically relevant (endo) phenotypes. This review examines the option of integrating mouse and human behavioural genetics to aid the identification of the putative underlying pathophysiological mechanisms and pharmacological targets for psychiatric disorders.
情绪和焦虑症的药物治疗长期以来一直依赖于50多年前偶然发现的单胺能药物和苯二氮䓬类药物。然而，这些治疗方法在治疗上并不充分，尽管最近开发的药物特别改善了副作用，但药物的疗效或有效率从根本上来说并没有提高。因此，有必要开发新的方法来识别新的机制，这些机制不仅基于症状学，还基于生物学相关的（内）表型。这篇综述探讨了整合小鼠和人类行为遗传学的选项，以帮助识别精神疾病潜在的病理生理机制和药理学靶点。
Zotero 插件